Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celgene Corp (CELG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,086,192
  • Shares Outstanding, K 787,320
  • Annual Sales, $ 11,229 M
  • Annual Income, $ 1,999 M
  • 36-Month Beta 1.77
  • Price/Sales 6.65
  • Price/Cash Flow 16.89
  • Price/Book 8.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.13 +1.50%
on 01/08/18
109.98 -6.66%
on 01/04/18
-4.41 (-4.12%)
since 12/19/17
3-Month
94.55 +8.57%
on 10/26/17
124.54 -17.58%
on 10/20/17
-33.31 (-24.50%)
since 10/19/17
52-Week
94.55 +8.57%
on 10/26/17
147.17 -30.25%
on 10/02/17
-10.97 (-9.65%)
since 01/19/17

Most Recent Stories

More News
Here's Why Agios (AGIO) Stock is Up More Than 50% in a Year

Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.

AGIO : 69.89 (+2.55%)
CELG : 102.65 (+0.91%)
SCMP : 17.95 (unch)
EXEL : 28.00 (+0.50%)
Will J&J's (JNJ) Pharma Segment Pull Up its Q4 Earnings?

J&J's (JNJ) pharma segment sales growth accelerated in the third quarter and we are likely to see, a continuation of the positive trend in the fourth quarter.

CELG : 102.65 (+0.91%)
JNJ : 147.36 (+0.30%)
MRK : 61.28 (+0.25%)
GSK : 38.20 (+0.08%)
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

CELG : 102.65 (+0.91%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label

Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.

CELG : 102.65 (+0.91%)
JNJ : 147.36 (+0.30%)
VRTX : 157.97 (+0.50%)
AMGN : 189.28 (+0.90%)
Company News For Jan 18, 2018

Companies In The News are: TIF,CSX,JUNO,CELG,FAST

TIF : 107.77 (-0.26%)
CELG : 102.65 (+0.91%)
CSX : 57.49 (-0.96%)
FAST : 53.74 (+0.85%)
JUNO : 67.81 (-4.99%)
M&A Waves Pushing Biotech ETFs Higher

The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.

BBC : 31.26 (+1.66%)
PBE : 50.44 (+1.35%)
CELG : 102.65 (+0.91%)
CNCR : 26.56 (+1.90%)
FBT : 133.08 (+0.77%)
JUNO : 67.81 (-4.99%)
J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

CELG : 102.65 (+0.91%)
JNJ : 147.36 (+0.30%)
ABBV : 104.64 (+0.80%)
GSK : 38.20 (+0.08%)
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

CELG : 102.65 (+0.91%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
3 Top-Ranked Drug Stocks that are Broker Favorites

With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

CELG : 102.65 (+0.91%)
COLL : 23.38 (+15.69%)
VRTX : 157.97 (+0.50%)
SNDX : 10.17 (+6.16%)
NVS : 86.94 (+0.61%)
GILD : 80.98 (-0.23%)
JUNO : 67.81 (-4.99%)
M&A Waves Pushing Biotech ETFs Higher

The new tax legislation has enticed U.S. companies to bring offshore cash back home, sparking waves of mergers and acquisitions.

BBC : 31.26 (+1.66%)
PBE : 50.44 (+1.35%)
CELG : 102.65 (+0.91%)
CNCR : 26.56 (+1.90%)
FBT : 133.08 (+0.77%)
JUNO : 67.81 (-4.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical...

See More

Key Turning Points

2nd Resistance Point 103.62
1st Resistance Point 103.13
Last Price 102.65
1st Support Level 102.08
2nd Support Level 101.52

See More

52-Week High 147.17
Fibonacci 61.8% 127.07
Fibonacci 50% 120.86
Fibonacci 38.2% 114.65
Last Price 102.65
52-Week Low 94.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.